Skip to main content
$30.33 -$0.19 (-0.6%)

04:00 PM EDT on 10/21/21

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Current Price $30.33 Mkt Cap $4.3B
Open $30.42 P/E Ratio 0.00
Prev. Close $30.33 Div. (Yield) $0.00 (0.0%)
Daily Range $30.18 - $31.03 Volume 721,557
52-Wk Range $29.01 - $64.37 Avg. Daily Vol. 1,002,203

Caps

How do you think NASDAQ:IONS will perform against the market?

Add Stock to CAPS Watchlist

All Players

788 Outperform
36 Underperform
 

All-Star Players

120 Outperform
8 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:IONS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

oncqueen (55.08)
Submitted February 20, 2015

They have a new anticoagulant which in 300 humans, given preoperatively for knee replacement, yielded NO clots (as opposed to 15% for Lovenox) and a bleeding risk of 5%, compared to 8% for Lovenox. This is a game-changer.

rofgile (99.57)
Submitted December 10, 2010

RNAi, please die.

Recent Community Commentary

Read the most recent pitches from players about IONS.

Recs

0
Member Avatar TMFAdriaCimino (20.27) Submitted: 7/3/2021 6:07:34 PM : Outperform Start Price: $40.22 NASDAQ:IONS Score: -29.18

Ionis has several candidates in the pipeline and expects to have at least 12 commercialized products by 2026. If that happens, we can expect a big increase in revenue over the coming years.

Recs

0
Member Avatar MKWas (< 20) Submitted: 2/18/2021 3:01:53 PM : Outperform Start Price: $57.84 NASDAQ:IONS Score: -63.56

A leaders in antisense oligonucleotides, an emerging technology used to control messenger RNA .

Recs

0
Member Avatar IndyAnthony (82.68) Submitted: 2/5/2021 11:57:00 PM : Underperform Start Price: $60.59 NASDAQ:IONS Score: +66.49

This biotech pharma company has out performed the S&P 500 over the last 10 years by hundreds of percent, but over the last 5 years, IONS has lost to the market by almost 30%, with most of those losses coming in 2020. The Founders are still involved, but institutions own almost 87% of the company. Despite collaborations with Roche, Biogen, and AstraZeneca, I think this company will underperform the market over the next 5-10 years.

Leaderboard

Find the members with the highest scoring picks in IONS.

Score Leader

yosemitebean

yosemitebean (36.44) Score: +594.49

The Score Leader is the player with the highest score across all their picks in IONS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
uclajphil6 34.46 1/7/2009 Underperform 3W $13.98 +116.95% +408.52% +291.57 0 Comment
JerryDreamer < 20 8/17/2009 Underperform 3W $15.37 +97.33% +361.17% +263.84 1 Comment
Supernanny543 42.14 8/5/2008 Underperform 3W $17.31 +75.22% +269.01% +193.80 0 Comment
CRAMERSUKS 67.19 9/2/2008 Underperform 5Y $17.94 +69.06% +259.77% +190.71 1 Comment
schwah5 81.25 7/30/2008 Underperform NS $16.61 +82.60% +268.51% +185.91 0 Comment
Geo113 < 20 4/14/2008 Underperform 3Y $16.13 +88.03% +254.88% +166.85 1 Comment
showmethemoney08 < 20 2/5/2008 Underperform 3M $15.88 +90.99% +247.82% +156.83 0 Comment
leafjumper 83.88 3/20/2008 Underperform 5Y $14.34 +111.51% +261.79% +150.28 1 Comment
OriginalBarnacle 48.89 5/6/2013 7/1/2013 Underperform 1Y $22.50 +34.80% +180.94% +146.14 0 Comment
DorkRockerGrrl 70.79 3/20/2008 Underperform 3M $14.20 +113.59% +258.34% +144.75 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IONS.